FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials
F Petrelli, K Borgonovo, M Cabiddu, M Ghilardi… - Clinical colorectal …, 2013 - Elsevier
Irinotecan and infusional bolus 5-fluorouracil (5-FU)-based chemotherapy (FOLFIRI [5-
fluorouracil, folinic acid, irinotecan])+ bevacizumab (FOLFIRI-B) is 1 of the cornerstones of …
fluorouracil, folinic acid, irinotecan])+ bevacizumab (FOLFIRI-B) is 1 of the cornerstones of …
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and …
C Cremolini, F Loupakis, C Antoniotti, C Lupi… - The Lancet …, 2015 - thelancet.com
Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and
irinotecan) plus bevacizumab significantly improved progression-free survival of patients …
irinotecan) plus bevacizumab significantly improved progression-free survival of patients …
Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin …
S Madajewicz, DM Waterhouse, PS Ritch… - Investigational new …, 2012 - Springer
Purpose To assess safety and efficacy of folinic acid, 5-fluorouracil, gemcitabine (FFG) and
folinic acid, fluorouracil, oxaliplatin (FOLFOX4) regimens with added bevacizumab as first …
folinic acid, fluorouracil, oxaliplatin (FOLFOX4) regimens with added bevacizumab as first …
[HTML][HTML] Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
E Van Cutsem, F Rivera, S Berry, A Kretzschmar… - Annals of …, 2009 - Elsevier
Background Bevacizumab significantly improves survival when added to chemotherapy for
metastatic colorectal cancer (mCRC). The Bevacizumab Expanded Access Trial (BEAT) …
metastatic colorectal cancer (mCRC). The Bevacizumab Expanded Access Trial (BEAT) …
“CHARTA”: FOLFOX/Bevacizumab vs. FOLFOXIRI/Bevacizumab in advanced colorectal cancer—Final results, prognostic and potentially predictive factors from the …
HJ Schmoll, FM Meinert, F Cygon, B Garlipp… - 2017 - ascopubs.org
3533 Background: FOLFOXIRI/Bevacizumab (Bev) is superior to FOLFIRI/Bev in the TRIBE
trial (F Loupakis, NEJM 2014). The CHARTA trial was developed parallel to TRIBE with the …
trial (F Loupakis, NEJM 2014). The CHARTA trial was developed parallel to TRIBE with the …
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the …
A Stein, G Glockzin, A Wienke, D Arnold, T Edelmann… - BMC cancer, 2012 - Springer
Background More than half of patients with colorectal cancer will develop metastatic disease
either evident at the time of initial diagnosis or during their course of disease. Besides …
either evident at the time of initial diagnosis or during their course of disease. Besides …
Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial
Y Horita, Y Yamada, K Kato, Y Hirashima… - International journal of …, 2012 - Springer
Objective FOLFIRI is a standard chemotherapy regimen for the treatment of metastatic
colorectal cancer. Although some studies have shown its efficacy in combination with …
colorectal cancer. Although some studies have shown its efficacy in combination with …
Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX–bevacizumab or FOLFIRI–bevacizumab: results …
JC Bendell, TS Bekaii-Saab, AL Cohn… - The …, 2012 - academic.oup.com
Abstract Background. The Avastin® Registry: Investigation of Effectiveness and Safety
(ARIES) study is a prospective, community-based observational cohort study that evaluated …
(ARIES) study is a prospective, community-based observational cohort study that evaluated …
FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE …
F Loupakis, C Cremolini, G Masi, S Lonardi, V Zagonel… - 2013 - ascopubs.org
336 Background: First-line FOLFOXIRI demonstrated superior activity and efficacy compared
to FOLFIRI. Moreover, the outcome is improved by the addition of bev to first-line doublets. A …
to FOLFIRI. Moreover, the outcome is improved by the addition of bev to first-line doublets. A …
A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second …
R Cao, S Zhang, D Ma, L Hu - Medical oncology, 2015 - Springer
Bevacizumab is an anti-VEGF human monoclonal antibody suitable for chemotherapy for
patients with metastatic colorectal cancer (mCRC). This study investigated the efficacy and …
patients with metastatic colorectal cancer (mCRC). This study investigated the efficacy and …